Nitronal® IV Infusion Approved for Sale in Mexico

Charlotte, North Carolina, and Guadalajara, Mexico – (November 8, 2005) – BurnsAdler Pharmaceuticals, Inc. (“BurnsAdler”) announced today that it’s regulatory application for Nitronal® IV Infusion has received approval from the Ministry of Health in Mexico. Nitronal® IV Infusion, a unique presentation of glyceryl trinitrate, is a pre-diluted, isotonic aqueous infusion solution with a glyceryl trinitrate concentration of 1mg/ml. The product is indicated for the treatment of severe angina pectoris, acute myocardial infarction, acute left-ventricular failure, hypertensive crisis with cardiac decompensation, controlled hypotension, catheter induced coronary spasms and increase of ischemia tolerance during PTCA. BurnsAdler will be co-marketing Nitronal® IV Infusion with its partner Laboratorios PiSA S.A. de C.V. (“PiSA”).

Bryan Somerville, BurnsAdler’s Executive Vice President commented, “We are very pleased to announce that the Mexican Government has approved our marketing application for Nitronal® IV Infusion. Our co-marketing partner, PiSA, is a leading supplier of hospital and emergency pharmaceutical products in Mexico and will be assisting us in marketing and distributing this life-saving therapy. The regulatory approval process was smooth and we are pleased to be formally launching the product during the first quarter of 2006.”

Nitronal® IV Infusion is a water-based isotonic solution that does not require dilution prior to use and contains no alcohol, solvents or preservatives. When compared to isosorbide dinitrate or ISDN intravenous solutions, the product also demonstrates many clinically significant benefits which allow physicians to better manage patients pharmacologically. The most significant of these benefits include a statistically significant shorter half-life and the earlier and more predictable termination of haemodynamic effects. Nitronal® IV Infusion reduces heart preload, the most important physiopathological effect in the acute myocardial infarction indication. Nitronal® IV Infusion’s effects generally cease within thirty minutes following the infusion whereas the effects of an ISDN infusion typically lasts between one and two hours. ISDN solutions also demonstrate a higher risk of significant hypotonia, which could lead to serious complications for the infarct patient when compared to Nitronal® IV Infusion.

BurnsAdler is a specialty pharmaceutical company that in-licenses and promotes products in Europe, South America, Latin America, Canada and the Caribbean. BurnsAdler’s portfolio currently includes products in the following fields: cardiovascular, orthopedic, anti-epileptic and hospital.

For additional information about this news release contact Bryan Somerville at +1.704.552.8410 Ext. 223. Find additional information about BurnsAdler at www.burnsadler.com.